Blood-Brain Barrier and Peptides

The blood-brain barrier (BBB) is the primary obstacle to CNS-targeted peptide therapeutics. This highly selective endothelial barrier permits passage of essential nutrients while excluding most large and hydrophilic molecules, including the majority of peptides.

Structure of the Blood-Brain Barrier

The BBB consists of brain microvascular endothelial cells connected by:

• Tight junctions: Claudins, occludin, and junction adhesion molecules create a paracellular barrier with electrical resistance exceeding 1500 ohm-centimeters squared
• Continuous basement membrane: Provides structural support and further restricts passage
• Astrocyte foot processes: Cover approximately 99 percent of the endothelial surface
• Pericytes: Regulate BBB properties and maintain barrier integrity

These components create a barrier with transendothelial electrical resistance 100-1000 times greater than peripheral capillaries.

Why Peptides Cannot Cross the BBB

Peptides face multiple barriers:

1. Size exclusion: The paracellular pathway is sealed by tight junctions, preventing passage of molecules larger than approximately 500 daltons
2. Hydrophilicity: Peptides are generally hydrophilic, impeding transcellular diffusion across the lipid bilayer
3. Efflux transporters: P-glycoprotein and other ABC transporters actively pump substrates back into the bloodstream
4. Metabolic degradation: Neuropeptidases on both luminal and abluminal surfaces degrade peptides during transit

Strategies for BBB Peptide Delivery

Receptor-Mediated Transcytosis

The BBB expresses receptors that transport ligands into the brain. Exploiting these endogenous pathways enables peptide delivery:

• Transferrin receptor: Anti-transferrin receptor antibodies conjugated to peptides facilitate receptor-mediated transcytosis
• Insulin receptor: Insulin-derived peptides or antibodies targeting the insulin receptor have shown promise
• LRP1: Angiopep-2, derived from aprotinin, targets LRP1 and has entered clinical trials for brain delivery

Cell-Penetrating Peptides

Short cationic or amphipathic peptides directly cross cell membranes:

• TAT peptide: Derived from HIV-1 transactivator of transcription
• Penetratin: From Antennapedia homeodomain
• Synthetic CPPs: Polyarginine sequences, transportan, and amphipathic designs

CPPs carry cargo either covalently conjugated or complexed non-covalently. However, BBB penetration efficiency in vivo remains debated.

Intranasal Delivery

The nasal pathway offers direct nose-to-brain delivery bypassing the BBB:

• Peptides travel along olfactory and trigeminal nerve pathways
• The olfactory region provides direct access to the CNS
• Avoids first-pass metabolism and systemic distribution
• Limitations include variable bioavailability and limited nasal surface area

Nanoparticle Carriers

Encapsulation in nanoparticles protects peptides from degradation and facilitates transport:

• Liposomes: Phospholipid vesicles can be surface-modified with targeting ligands
• Polymeric nanoparticles: PLGA and chitosan-based systems provide controlled release
• Solid lipid nanoparticles: Cross the BBB through endocytosis

The 5 Rs of Brain Delivery

Remember the requirements for successful CNS peptide delivery with 5 Rs:

• Receptor targeting to initiate transcytosis
• Resistance to enzymatic degradation
• Release at the target site
• Retention in brain tissue
• Recovery without excessive efflux

Clinical Applications

BBB-crossing peptides are being developed for neurodegenerative diseases (Alzheimer’s, Parkinson’s), brain tumors, stroke, and pain management. Understanding BBB biology remains essential for rational design of CNS-targeted peptide therapeutics.